New hope for Tough-to-Treat kidney cancer? early trial tests novel drug combo
NCT ID NCT07401875
Summary
This early-stage study aims to see if a new drug called HC-7366, when combined with standard immunotherapy drugs (nivolumab with or without ipilimumab), can help control advanced clear cell kidney cancer. It will enroll about 35 adults to test the safety of these combinations and see if they can shrink or stabilize tumors. The main goal is to find a safe dose and see if the treatment shows early signs of working against the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.